Psychopharmacology in children and adolescents: unmet needs and opportunities
Psychopharmacology in children and adolescents: unmet needs and opportunities
Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside possible risks to consider, regarding the pharmacological treatment of mental health conditions in children and adolescents. In this Position Paper, we highlight and address these unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology–Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency. We present and discuss the evidence base for medications currently used for mental disorders in children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and legislative framework, and innovations in the way research is conducted, reported, and promoted.
143-154
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Puper-Ouakil, Diane
7616acc2-27bc-4700-bbbd-45ca6fd245c6
Apter, Alan
7a1cff3f-9120-47c7-a225-40f8552845fb
February 2024
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Puper-Ouakil, Diane
7616acc2-27bc-4700-bbbd-45ca6fd245c6
Apter, Alan
7a1cff3f-9120-47c7-a225-40f8552845fb
Cortese, Samuele, Puper-Ouakil, Diane and Apter, Alan
,
et al.
(2024)
Psychopharmacology in children and adolescents: unmet needs and opportunities.
The Lancet Psychiatry, 11 (2), .
(doi:10.1016/S2215-0366(23)00345-0).
Abstract
Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside possible risks to consider, regarding the pharmacological treatment of mental health conditions in children and adolescents. In this Position Paper, we highlight and address these unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology–Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency. We present and discuss the evidence base for medications currently used for mental disorders in children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and legislative framework, and innovations in the way research is conducted, reported, and promoted.
Text
Cortese et al. MAIN_TEXT_R1_CLEAN
- Accepted Manuscript
More information
e-pub ahead of print date: 7 December 2023
Published date: February 2024
Additional Information:
Publisher Copyright:
© 2024 Elsevier Ltd
Identifiers
Local EPrints ID: 486705
URI: http://eprints.soton.ac.uk/id/eprint/486705
ISSN: 2215-0366
PURE UUID: 5899b7fa-0fcd-4148-8998-d39600c65d70
Catalogue record
Date deposited: 02 Feb 2024 17:30
Last modified: 18 Jul 2024 04:01
Export record
Altmetrics
Contributors
Author:
Diane Puper-Ouakil
Author:
Alan Apter
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics